Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Pharm Biomed Anal ; 44(1): 79-84, 2007 May 09.
Artigo em Inglês | MEDLINE | ID: mdl-17379465

RESUMO

During development of solid dosage products, a pharmaceutical manufacturer is typically required to propose dissolution acceptance criteria unless the product falls into Biopharmaceutics Classification System (BCS) class I, in which case a disintegration test may be used. At the time of filing the new drug application (NDA) or common technical document (CTD), the manufacturer has already met with regulatory agencies to discuss and refine dissolution strategy. The dissolution acceptance criteria are based on stability and batch history data and are often arrived at by considering the percentage of batches that pass United States Pharmacopeia (USP) criteria at Stage 1 (S(1)), when in fact, the product is deemed unacceptable only when a batch fails USP criteria at Stage 3 (S(3)) [H. Saranadasa, Disso. Technol. 7 (2000) 6-7, 18 [1]]. Calculating the probability of passing (or failing) dissolution criteria at S(1), S(2), or S(3) can assist a manufacturer in determining appropriate acceptance criteria. This article discusses a general statistical method that was developed to assess the probability of passing the multistage USP test for dissolution and how it was applied to an immediate release tablet formulation. In this case, acceptance criteria were set and the analysis was conducted to assess the probabilities of passing or failing based on this acceptance criterion. Whether the acceptance criteria were relevant to the product was also considered. This mathematical approach uses a Monte Carlo simulation and considers a range of values for standard deviation and mean of historical data.


Assuntos
Preparações Farmacêuticas/normas , Probabilidade , Comprimidos/normas , Tecnologia Farmacêutica/métodos , Disponibilidade Biológica , Química Farmacêutica , Simulação por Computador , Formas de Dosagem , Método de Monte Carlo , Farmacopeias como Assunto , Estudos de Amostragem , Design de Software , Solubilidade , Estados Unidos
2.
J Pharm Biomed Anal ; 44(5): 1064-71, 2007 Sep 03.
Artigo em Inglês | MEDLINE | ID: mdl-17560750

RESUMO

A dissolution method with high performance liquid chromatography (HPLC) analysis was validated for an immediate release low dose tablet formulation. The method was validated to meet requirements for a global regulatory filing and this validation included specificity, precision, linearity, accuracy and range. Validation of precision included an intermediate precision study using an experimental design in order to satisfy Japanese regulatory requirements. In addition, filter suitability, standard and sample solution stability and method robustness were demonstrated. A statistical design of experiments was used for the robustness evaluation of both the dissolution method and the HPLC analysis method. All results were acceptable and confirmed that the method is suitable for its intended use.


Assuntos
Química Farmacêutica/métodos , Cromatografia Líquida de Alta Pressão/métodos , Moduladores de Receptor Estrogênico/análise , Pirrolidinas/análise , Tecnologia Farmacêutica/métodos , Tetra-Hidronaftalenos/análise , Relação Dose-Resposta a Droga , Moduladores de Receptor Estrogênico/química , Estrutura Molecular , Pirrolidinas/química , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Solubilidade , Comprimidos , Tetra-Hidronaftalenos/química , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA